Correspondence

OPEN ACCESS

Received: Jun 17, 2018

Revised: Jul 10, 2018

Accepted: Jul 10, 2018

Correspondence to

Giorgio Bogani

Department of Gynecologic Oncology, IRCCS
National Cancer Institute, Via Venezian 1,
20133 Milan, Italy.

E-mail: giorgiobogani@yahoo.it
giorgio.bogani@istitutotumori.mi.it

Copyright © 2018. Asian Society of

Gynecologic Oncology, Korean Society of
Gynecologic Oncology

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Giorgio Bogani

<https://orcid.org/0000-0001-8373-8569>

Umberto Leone Roberti Maggiore

<https://orcid.org/0000-0002-3744-2668>

Francesco Raspagliesi

<https://orcid.org/0000-0002-4740-7794>

Conflict of Interest

No potential conflict of interest relevant to this
article was reported.

Author Contributions

Conceptualization: B.G., L.R.M.U., R.F.;

Supervision: B.G., R.F.; Visualization: R.F.;

Writing - original draft: B.G., L.R.M.U., R.F.;

Writing - review & editing: B.G., L.R.M.U., R.F.

Lynch syndrome – Muir-Torre variant: implication in gynecologic oncology

Giorgio Bogani , **Umberto Leone Roberti Maggiore** , **Francesco Raspagliesi**

Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy

First described by Muir et al. in 1967 [1] and Torre in 1968 [2], Muir-Torre syndrome (MTS) is a rare hereditary condition which is considered as an uncommon variant of Lynch syndrome [3]. In current literature, less than 300 cases of patients affected by MTS have been described [2]. It has been reported that MTS is associated with an increased risk of several types of cancer, particularly colonic, genitourinary and skin tumors.

The concomitant presence of the following criteria is mandatory to diagnose MTS: 1) single or multiple sebaceous gland tumor(s) (either adenoma, epithelioma, carcinoma) or multiple keratoacanthomas and 2) at least a single visceral cancer. An association with non-Hodgkin lymphoma is reported [3].

Women's lifetime risk of developing gynecological malignancies is increased if they are diagnosed with MTS (risk estimated for endometrial cancer from 20% to 60%; risk estimated for ovarian cancer from 9% to 12%). In particular, the increased risk is related to both low malignant potential (i.e., borderline) and invasive ovarian tumor. However, knowledge and awareness of MTS is still limited. Here, we reviewed the current evidence regarding MTS in order to evaluate the implication of MTS in the gynecologic oncology field.

MTS is caused by inherited mutations that impair the DNA mismatch repair (MMR) such as MutL homolog 1 (*MLH1*), MutS protein homolog 2 (*MSH2*), and rarely mutS homolog 6 (*MSH6*). MTS has an autosomal dominant pattern of inheritance in about 60% of cases and it is characterized by a high degree of penetrance and variable expression [3].

Searching the literature, we were able to detect only a small amount of data regarding the implication of MTS for gynecologic disease. To date, only few reports reported an association of MTS with cervical adenocarcinoma, carcinoma of the uterine corpus and of the ovary [4]. Cases of sebaceous tumor growing within ovarian teratoma are reported as well [5]. MTS represents a variant of Lynch syndrome, characterized by pathognomonic features (i.e., cutaneous tumors) that can help for an easier and more intriguing diagnosis. Interestingly, sebaceous and visceral tumors occurring along with MTS have been described to be lower aggressive than their sporadic counterparts [3].

Although MTS is considered to be an uncommon condition compared with Lynch syndrome, the prevalence of MTS is likely to be underreported. South et al. [6], evaluated the frequency of MTS in Lynch syndrome families. Among 50 Lynch syndrome families (ascertained from

a population-based series of cancer patients who were newly diagnosed with colorectal or endometrial carcinoma), they observed MTS in 28% (14/50) of the families evaluated and in 9.2% (14/152) of the individuals with Lynch syndrome [3]. However, literature reports also a subgroup of sporadic cases, not related to deficiency in MMR genes [3]. The pathogenesis of sporadic MTS (approximately 35% of all MTS) remains unclear and challenging [3]. Biological, molecular, and immuno-histochemical characterizations should be used for identifying patients at risk for MTS [3].

MST is defined as the occurrence of at least 1 sebaceous-gland tumor, or keratoacanthoma, in conjunction with visceral tumor(s).

Diagnosis of gynecological malignancies, along with simultaneous or sequential cutaneous tumors and keratoacanthomas, might indicate the presence of MTS. Patients and their relatives should be counseled about this risk of future occurrence of gynecologic malignancies. Reconstruction of detailed family history could allow the identification or the suspicion of MTS, and the selection of patients in whom to proceed with clinical, molecular, and immuno-histochemical examinations. Knowledge and awareness on MTS should be improved within gynecologic oncology community.

REFERENCES

1. Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. *Br J Surg* 1967;54:191-5.
[PUBMED](#) | [CROSSREF](#)
2. Torre D. Multiple sebaceous tumors. *Arch Dermatol* 1968;98:549-51.
[PUBMED](#) | [CROSSREF](#)
3. John AM, Schwartz RA. Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. *J Am Acad Dermatol* 2016;74:558-66.
[PUBMED](#) | [CROSSREF](#)
4. Smith J, Crowe K, McGaughran J, Robertson T. Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir-Torre syndrome. *Ann Diagn Pathol* 2012;16:485-8.
[PUBMED](#) | [CROSSREF](#)
5. Nair N, Curtin JP, Mittal K, Hiotis KL. Cervical adenocarcinoma in a patient with Lynch syndrome, Muir-Torre variant. *J Clin Oncol* 2012;30:e5-6.
[PUBMED](#) | [CROSSREF](#)
6. South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. *J Natl Cancer Inst* 2008;100:277-81.
[PUBMED](#) | [CROSSREF](#)